Study of VA Combined With HAAG Regimen in Newly Diagnosed Intermediate and High-risk AML Patients

Other illness

• Patients with a second malignancy requiring treatment.
• Patients with uncontrolled active infection.
• Patients with HIV infection.
• Patients with active hepatitis B or hepatitis C infection.

Lab values

• Patients with left ventricular ejection fraction \< 0.5 by echocardiography or grade III/IV cardiovascular dysfunction according to the New York Heart Association Classification.
• Patients with hepatic and renal inadequacy: total serum bilirubin \>=2.0 mg/dl, AST \>=3 times ULN, serum creatinine clearance (Ccr) \<50 ml / min.

Other

• AML transformed with chronic myelogenous leukemia.
• Acute promyelocytic leukemia (type M3).
• Patients with arterial oxygen saturation (SpO 2) was \<95%.
• Patients with other commodities that the investigators considered not suitable for the enrollment.

• Newly diagnosed intermediate and high-risk AML according to the WHO (2022) classification of acute myeloid leukemia (non-APL).
• Age 18-65.
• ECOG score: 0-2.
• No history of previous chemotherapy or target therapy.
• Serum total bilirubin \<= 2 times the upper limit of normal (ULN), alanine aminotransferase (ALT) \<= 1.5 times ULN, aspartate aminotransferase (AST) \<=1.5 times ULN;
• Creatinine clearance rate \>=30 mL/min;
• Serum lipase \<= 1.5 times ULN, amylase \<= 1.5 times ULN;
• Capable to understand and willing to participate in this study, signed the informed consent form.